Trial Profile
A Phase 1 Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2014
Price :
$35
*
At a glance
- Drugs AVN 944 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 10 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 10 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 10 Mar 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.